LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

Search

Crinetics Pharmaceuticals Inc

Deschisă

SectorSănătate

35.26 1.12

Rezumat

Modificarea prețului

24h

Curent

Minim

34.61

Maxim

35.75

Indicatori cheie

By Trading Economics

Venit

-19M

-116M

Vânzări

670K

1M

Marjă de profit

-11,216.004

Angajați

437

EBITDA

-19M

-129M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+99.63% upside

Dividende

By Dow Jones

Următoarele câștiguri

11 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

275M

2.9B

Deschiderea anterioară

34.14

Închiderea anterioară

35.26

Sentimentul știrilor

By Acuity

4%

96%

2 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 sept. 2025, 23:59 UTC

Achiziții, Fuziuni, Preluări

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept. 2025, 22:02 UTC

Principalele dinamici ale pieței

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept. 2025, 17:01 UTC

Principalele dinamici ale pieței

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept. 2025, 17:01 UTC

Principalele dinamici ale pieței

Tron Shares Rise After New Investment From Bravemorning

8 sept. 2025, 16:14 UTC

Principalele dinamici ale pieței

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept. 2025, 16:13 UTC

Principalele dinamici ale pieței

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept. 2025, 21:47 UTC

Principalele dinamici ale pieței

Microsoft Signs $17.4B AI Deal With Nebius

8 sept. 2025, 21:33 UTC

Achiziții, Fuziuni, Preluări

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept. 2025, 21:20 UTC

Achiziții, Fuziuni, Preluări

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept. 2025, 21:19 UTC

Achiziții, Fuziuni, Preluări

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept. 2025, 20:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept. 2025, 16:59 UTC

Market Talk
Achiziții, Fuziuni, Preluări

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 16:16 UTC

Câștiguri

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparație

Modificare preț

Crinetics Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

99.63% sus

Prognoză pe 12 luni

Medie 71.09 USD  99.63%

Maxim 97 USD

Minim 36 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCrinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

11

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

30.39 / 33.46Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

2 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat